Cited by 854Bone health and treatmentsAngiogenesis and VEGF in CancerBone Metabolism and Diseases

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

Wood, Jeanette, Bonjean, Karine, Ruetz, Stephan, Bellahcène, Akeila, Devy, Laetitia, Foidart, Jean Michel, Castronovo, Vincent, Green, Jonathan R.·2002·The Journal of Pharmacology and Experimental Therapeutics

DOI 10.1124/jpet.102.035295

Open this paper in CoChat — free account

Abstract

Bisphosphonate drugs inhibit osteoclastic bone resorption and are widely used to treat skeletal complications in patients with tumor-induced osteolysis. We now show that zoledronic acid, a new generation bisphosphonate with a heterocyclic imidazole substituent, is also a potent inhibitor of angiogenesis. In vitro, zoledronic acid inhibits proliferation of human endothelial cells stimulated with fetal calf serum, basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (IC(50) values 4.1, 4.2, and 6.9 microM, respectively), and modulates endothelial cell adhesion and migration. In cultured aortic rings and in the chicken egg chorioallantoic membrane assay, zoledronic acid reduces vessel sprouting. When administered systemically to mice, zoledronic acid potently inhibits the angiogenesis induced by subcutaneous implants impregnated with bFGF [ED(50), 3 microg/kg (7.5 nmol/kg) s.c.]. These findings indicate that zoledronic acid has marked antiangiogenic properties that could augment its efficacy in the treatment of malignant bone disease and extend its potential clinical use to other diseases with an angiogenic component.

Integrity signals

Registry

Crossref · 10.1124/jpet.102.035295

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological Neovascularization
Asahara, T., Masuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., Kearne, M., Magner, M., & Isner, J. M. (1999) · Circulation Research · doi:10.1161/01.res.85.3.221 · Cited by 3,263
Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Bisphosphonates: Mechanisms of Action
Fleisch, H. A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,109
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D., Mundy, G. R., & Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,039
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 844
Self-citation
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I., Solomayer, E., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D. R., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices.
Montesano, R., Orci, L., & VASSALLI, P. (1983) · The Journal of Cell Biology · doi:10.1083/jcb.97.5.1648 · Cited by 647
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
Berenson, J. R., Lichtenstein, A. K., Porter, L., Dimopoulos, M. A., Bordoni, R. E., George, S., Lipton, A., Keller, A. M., Ballester, O., Kovacs, M. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 645

Flagged first, then by citations

Show all 33 references

1 of the 33 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Boissier, 2020, Zoledronic acid inhibits in vivo experimental angiogenesis (abstract B3)., Bone, 30, 38S
Bonjean, 2002, Zoledronic acid inhibits human endothelial cell adhesion to vitronectin and selectively alters the expression of extracellular matrix cell surface receptors (abstract B4)., Bone, 30, 38S

Sorted by citations

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
Ruggiero, S. L., Dodson, T. B., Fantasia, J. E., Goodday, R. H. B., Aghaloo, T. L., Mehrotra, B., & O’Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,975
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,299
Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,034
Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment
Marx, R. E., Sawatari, Y., Fortin, M., & Broumand, V. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.07.010 · Cited by 1,635
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,242
American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update
Ruggiero, S. L., Dodson, T. B., Aghaloo, T. L., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,209
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., PAPADIMITRIOU, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8670 · Cited by 1,136
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.
Giraudo, E., Inoue, M., & Hanahan, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422087 · Cited by 700
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
Folkman, J. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.015 · Cited by 675
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Badros, A. Z., Weikel, D. S., Salama, A., Goloubeva, O. G., Schneider, A., Rapoport, A. P., Fenton, R. G., Gahres, N., Sausville, E. A., Ord, R. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2465 · Cited by 583
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Fournier, P. G. J., Boissier, S., Filleur, S., Guglielmi, J., Cabon, F., Colombel, M. C., & Clézardin, P. (2002) · PubMed · Cited by 562
The role of subchondral bone remodeling in osteoarthritis: Reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model
Hayami, T., Pickarski, M., Wesolowski, G. A., Mclane, J., Bone, A., Destefano, J., Rodan, G. A., & Duong, L. T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20124 · Cited by 574
γδ T cells for immune therapy of patients with lymphoid malignancies
Wilhelm, M., Kunzmann, V., Eckstein, S., Reimer, P., Weißinger, F., Ruediger, T. M., & Tony, H. (2003) · Blood · doi:10.1182/blood-2002-12-3665 · Cited by 551
Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management
Ruggiero, S. L., Fantasia, J. E., & Carlson, E. R. (2006) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2006.06.004 · Cited by 500
Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone
Migliorati, C. A., Schubert, M. M., Peterson, D. E., & Sêneda, L. M. (2005) · Cancer · doi:10.1002/cncr.21130 · Cited by 489
Bisphosphanates and Oral Cavity Avascular Bone Necrosis
Migliorati, C. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.99.132 · Cited by 475
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El‐Rayes, B. F., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 479
Managing the care of patients with bisphosphonate-associated osteonecrosis
Migliorati, C. A., Casiglia, J., Epstein, J. B., Jacobsen, P. L., Siegel, M. A., & Woo, S. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0108 · Cited by 463
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
Allen, M. R., & Burr, D. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.007 · Cited by 449
Bisphosphonates: Preclinical Review
Green, J. R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-3 · Cited by 406
Self-citation
Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review
Fliefel, R. M., Troeltzsch, M., Kühnisch, J., Ehrenfeld, M., & Otto, S. (2015) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.01.026 · Cited by 366
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.
Santini, D., Vincenzi, B., Dicuonzo, G., Avvisati, G., Massacesi, C., Battistoni, F., Gavasci, M., Rocci, L., Tirindelli, M. C., Altomare, V., et al. (2003) · PubMed · Cited by 350
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
Migliorati, C. A., Siegel, M. A., & Elting, L. S. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70726-4 · Cited by 340
Endogenous angiogenesis inhibitors
Folkman, J. (2004) · Apmis · doi:10.1111/j.1600-0463.2004.apm11207-0809.x · Cited by 321
Inhibition of Oral Mucosal Cell Wound Healing by Bisphosphonates
Landesberg, R., Cozin, M., Cremers, S., Woo, V., Kousteni, S., Sinha, S., Garrett‐Sinha, L. A., & Raghavan, S. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.01.026 · Cited by 321
Antitumor effects of bisphosphonates
Green, J. R. (2003) · Cancer · doi:10.1002/cncr.11128 · Cited by 311
Self-citation
A Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics
Pazianas, M., Miller, P. D., Blumentals, W. A., Bernal, M., & Kothawala, P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.008 · Cited by 300
Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies
Boonyapakorn, T., Schirmer, I., Reichart, P. A., Sturm, I., & Massenkeil, G. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2007.11.012 · Cited by 278
Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons
Yoneda, T., Hagino, H., Sugimoto, T., Ohta, H., Takahashi, S., Soen, S., Taguchi, A., Toyosawa, S., Nagata, T., & Urade, M. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0162-7 · Cited by 279
Osteonecrosis of the Jaw in a Patient on Denosumab
Aghaloo, T. L., Felsenfeld, A. L., & Tetradis, S. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.10.010 · Cited by 277
Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases
Sebastián, J. V. B., Murillo, J., Jimenez, Y., Poveda, R., Masanet, M. Á. M., Sanchis, J. M., Donat, F. J. S., & Scully, C. M. (2005) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2004.00269.x · Cited by 267
Bisphosphonate Osteochemonecrosis (Bis-Phossy Jaw): Is This Phossy Jaw of the 21st Century?
Hellstein, J. W., & Marek, C. L. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.01.010 · Cited by 267
Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival
Croucher, P. I., Raeve, H. D., Perry, M., Hijzen, A., Shipman, C. M., Lippitt, J., Green, J., Marck, E. V., Camp, B. V., & Vanderkerken, K. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.482 · Cited by 267
Self-citation
Hormesis and medicine
Calabrese, E. J. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03243.x · Cited by 269
Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates
Kimmel, D. B. (2007) · Journal of Dental Research · doi:10.1177/154405910708601102 · Cited by 253
Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone
Clines, G. A., & Guise, T. A. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00543 · Cited by 255
Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model
Hiraga, T., Williams, P. J., Ueda, A., Tamura, D., & Yoneda, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0325 · Cited by 245
Skeletal changes during and after spaceflight
Vico, L., & Hargens, A. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.37 · Cited by 236
Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone
Christodoulou, C., Pervena, A., Klouvas, G. D., Galani, E. P., Falagas, M. E., Tsakalos, G., Visvikis, A., Nikolakopoulou, A., Acholos, V., Karapanagiotidis, G. T., et al. (2009) · Oncology · doi:10.1159/000201931 · Cited by 230
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Lacy, M. Q., Dispenzieri, A. A., Gertz, M. A., Greipp, P. R., Gollbach, K. L., Hayman, S. R., Kumar, S. K., Lust, J. A., Rajkumar, S. V., Russell, S. J., et al. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1047 · Cited by 227
Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer
Ottewell, P. D., Mönkkönen, H., Jones, M., Lefley, D. V., Coleman, R., & Holen, I. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn240 · Cited by 224
Exploring the anti-tumour activity of bisphosphonates in early breast cancer
Winter, M. C., Holen, I., & Coleman, R. E. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.02.004 · Cited by 223
Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment
Ficarra, G., Beninati, F., Rubino, I., Vannucchi, A. M., Longo, G., Tonelli, P., & Prato, G. P. (2005) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2005.00842.x · Cited by 209
Adverse drug events in the oral cavity
Yuan, A., & Woo, S. (2014) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2014.09.009 · Cited by 200
Pathophysiology of Osteonecrosis of the Jaws
Aghaloo, T. L., Hazboun, R. C., & Tetradis, S. (2015) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2015.06.001 · Cited by 204
Bisphosphonates in cancer therapy
Stresing, V., Daubiné, F., Benzaïd, I., Mönkkönen, H., & Clézardin, P. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.07.007 · Cited by 205
Osteoclasts are important for bone angiogenesis
Cackowski, F. C., Anderson, J. L., Patrene, K. D., Choksi, R. J., Shapiro, S. D., Windle, J. J., Blair, H. C., & Roodman, G. D. (2010) · Blood · doi:10.1182/blood-2009-08-237628 · Cited by 188
Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice
Kobayashi, Y., Hiraga, T., Ueda, A., Wang, L., Matsumoto‐Nakano, M., Hata, K., Yatani, H., & Yoneda, T. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0128-9 · Cited by 187
Biomedical applications of bisphosphonates
Giger, E. V., Castagner, B., & Leroux, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.032 · Cited by 192
Bisphosphonate conjugation for bone specific drug targeting
Farrell, K. B., Karpeisky, A. M., Thamm, D. H., & Zinnen, S. P. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.06.007 · Cited by 186
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Musto, P., Petrucci, M. T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzoni, V., Andriani, A., D'Arena, G. F., Balleari, E., Pietrantuono, G., et al. (2008) · Cancer · doi:10.1002/cncr.23783 · Cited by 184
Breast tumour angiogenesis
Fox, S. B., Generali, D., & Harris, A. L. (2007) · Breast Cancer Research · doi:10.1186/bcr1796 · Cited by 184
Potential pathophysiological mechanisms in osteonecrosis of the jaw
Landesberg, R., Woo, V., Cremers, S., Cozin, M., Marolt, D., Vunjak‐Novakovic, G., Kousteni, S., & Raghavan, S. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05835.x · Cited by 178
Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients
Santini, D., Vincenzi, B., Galluzzo, S., Battistoni, F., Rocci, L., Venditti, O., Schiavon, G., Angeletti, S., Uzzalli, F., Caraglia, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0551 · Cited by 171
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
Santini, D., Gentilucci, U. V., Vincenzi, B., Picardi, A., Vasaturo, F., Cesa, A. L., Onori, N., Scarpa, S., & Tonini, G. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg401 · Cited by 167
Osteonecrosis of the Mandible or Maxilla Associated with the use of New Generation Bisphosphonates
Farrugia, M. C., Summerlin, D., Krowiak, E. J., Huntley, T. C., Freeman, S. B., Borrowdale, R. W., & Tomich, C. E. (2006) · The Laryngoscope · doi:10.1097/01.mlg.0000187398.51857.3c · Cited by 165
Adverse effects of bisphosphonates: current issues.
Diel, I., Bergner, R., & Grötz, K. A. (2007) · PubMed · Cited by 162
Osteonecrosis of the Jaw and the Role of Bisphosphonates: A Critical Review
Silverman, S. L., & Landesberg, R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.005 · Cited by 160
Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy
Estilo, C. L., Poznak, C. H. V., Wiliams, T., Bohle, G. C., Lwin, P. T., Zhou, Q. C., Riedel, E., Carlson, D. L., Schöder, H. M., Farooki, A., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0091 · Cited by 158
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
Montefusco, V., Gay, F., Spina, F., Miceli, R., Maniezzo, M., Ambrosini, M. T., Farina, L., Piva, S., Palumbo, A. P., Boccadoro, M., et al. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802483778 · Cited by 154
Infection and Medication-related Osteonecrosis of the Jaw
Katsarelis, H., Shah, N., Dhariwal, D. K., & Pazianas, M. (2015) · Journal of Dental Research · doi:10.1177/0022034515572021 · Cited by 151
Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy
Melo, M. D., & Obeid, G. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0110 · Cited by 151
Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the Jaws
Phal, P. M., Myall, R. W. T., Assael, L. A., & Weissman, J. L. (2007) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0518 · Cited by 149
Sequence‐ and schedule‐dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
Neville-Webbe, H. L., Rostami‐Hodjegan, A., Evans, C. A., Coleman, R. E., & Holen, I. (2004) · International Journal of Cancer · doi:10.1002/ijc.20602 · Cited by 147
Osteonecrosis of the Jaws and Bisphosphonate Therapy
Ruggiero, S., & Drew, S. J. (2007) · Journal of Dental Research · doi:10.1177/154405910708601101 · Cited by 147
THE MEDICAL MANAGEMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA: CURRENT TREATMENT CONSIDERATIONS
Kaplan, F. S., & Disorders, R. (2011) · Cited by 145
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS
Anastasilakis, A. D., Pepe, J., Napoli, N., Palermo, A., Magopoulos, C., Khan, A. A., Zillikens, M. C., & Body, J.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab888 · Cited by 143
Osteonecrosis of the Jaw and the Role of Macrophages
Pazianas, M. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq516 · Cited by 142
Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death
Bezzi, M., Hasmim, M., Bieler, G., Dormond, O., & Rüegg, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308114200 · Cited by 139
Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: An analysis of 31 cases with confocal laser scanning microscopy
Favia, G., Pilolli, G. P., & Maiorano, E. (2009) · Bone · doi:10.1016/j.bone.2009.05.008 · Cited by 138
The role of bisphosphonates in breast and prostate cancers.
Brown, J. E., Neville-Webbe, H. L., & Coleman, R. E. (2004) · Endocrine Related Cancer · doi:10.1677/erc.0.0110207 · Cited by 137
Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals
Magopoulos, C., Karakinaris, G., Telioudis, Z., Vahtsevanos, K., Dimitrakopoulos, I., Antoniadis, K., & Delaroudis, S. (2007) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2006.08.004 · Cited by 138
Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents
Aragon‐Ching, J. B., Ning, Y. M., Chen, C. C., Latham, L. L., Guadagnini, J.-P., Gulley, J. L., Arlen, P. M., Wright, J. J., Parnes, H. L., Figg, W. D., et al. (2009) · Cancer Investigation · doi:10.1080/07357900802208608 · Cited by 134
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic
Au, K. M., Satterlee, A., Min, Y., Tian, X., Kim, Y. S., Caster, J. M., Zhang, L., Zhang, T., Huang, L., & Wang, A. Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.018 · Cited by 134
Bisphosphonates: new therapeutic agents for the treatment of bone tumors
Heymann, D., Ory, B., Gouin, F., Green, J. R., & Rédiní, F. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.05.007 · Cited by 139
Self-citation
Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease
Dunstan, C. R., Felsenberg, D., & Seibel, M. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0688 · Cited by 135
Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
Grbic, J. T., Landesberg, R., Lin, S., Mesenbrink, P. G., Reid, I. R., Leung, P., Casas, N., Recknor, C. P., Hua, Y., Delmas, P. D., et al. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0017 · Cited by 134
Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Rusnati, M., & Presta, M. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781039689 · Cited by 133
Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy.
Melo, M. D., & Obeid, G. (2005) · PubMed · Cited by 132
Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients
Ferretti, G., Fabi, A., Carlini, P., Papaldo, P., Fei, P. C., Cosimo, S. D., Salesi, N., Giannarelli, D., Alimonti, A., Cocco, B. D., et al. (2005) · Oncology · doi:10.1159/000087286 · Cited by 131
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer
Zaghloul, M. S., Boutrus, R. R., Hossieny, H. A. E., Kader, Y. A., Elattar, I. A., & Nazmy, M. S. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0074-5 · Cited by 130
Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)
Wirth, M. P., Tammela, T. L. J., Cicalese, V., Veiga, F. G., Delaere, K. P. J., Miller, K., Tubaro, A., Schulze, M., Debruyne, F. M. J., Huland, H., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.014 · Cited by 130
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
Caraglia, M., Santini, D., Marra, M., Vincenzi, B., Tonini, G., & Budillon, A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01094 · Cited by 131
Zoledronic Acid-Related Angiogenesis Modifications and Survival in Advanced Breast Cancer Patients
Vincenzi, B., Santini, D., Dicuonzo, G., Battistoni, F., Gavasci, M., Cesa, A. L., Grilli, C., Virzì, V., Gasparro, S., Rocci, L., et al. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.144 · Cited by 129
Bisphosphonate‐related osteonecrosis of the jaw: an overview
Ruggiero, S. L. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05768.x · Cited by 127
Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
Newcomb, P. A., Trentham‐Dietz, A., & Hampton, J. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605555 · Cited by 126
Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro
Ziebart, T., Pabst, A. M., Klein, M. O., Kämmerer, P. W., Gauss, L., Brüllmann, D. D., Al‐Nawas, B., & Walter, C. (2009) · Clinical Oral Investigations · doi:10.1007/s00784-009-0365-2 · Cited by 128
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
WYNGAERT, T. V. D., Huizing, M. T., & Vermorken, J. B. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl294 · Cited by 125
Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect
Sharma, D., Ivanovski, S., SLEVIN, M. A., Hamlet, S. M., Pop, T. S., Brînzaniuc, K., Petcu, E. B., & Miroiu, R. I. (2013) · Vascular Cell · doi:10.1186/2045-824x-5-1 · Cited by 123
Antiangiogenic activity of β-eudesmol in vitro and in vivo
Tsuneki, H., Ma, E., Kobayashi, S., Sekizaki, N., Maekawa, K., Sasaoka, T., Wang, M., & Kimura, I. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.035 · Cited by 121
The dental implications of bisphosphonates and bone disease
Cheng, A., Mavrokokki, A., Carter, G., Stein, B. N., Fazzalari, N. L., Wilson, D., & Goss, A. N. (2005) · Australian Dental Journal · doi:10.1111/j.1834-7819.2005.tb00384.x · Cited by 121
Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature
FABBRO, M. D., Gallesio, G., & Mozzati, M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.015 · Cited by 119
Antiresorptives and Osteonecrosis of the Jaw
Yamashita, J., & McCauley, L. K. (2012) · Journal of Evidence Based Dental Practice · doi:10.1016/s1532-3382(12)70046-5 · Cited by 121
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases
Dimitrakopoulos, I., Magopoulos, C., & Karakasis, D. (2006) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2006.02.022 · Cited by 119
Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma
Brunello, A., Saia, G., Bedogni, A., Scaglione, D., & Basso, U. (2008) · Bone · doi:10.1016/j.bone.2008.08.132 · Cited by 117
The anti-tumour activity of bisphosphonates
Neville-Webbe, H. L., Holen, I., & Coleman, R. E. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00095-6 · Cited by 117
Diabetes as a Risk Factor for Medication-Related Osteonecrosis of the Jaw
Peer, A., & Khamaisi, M. (2014) · Journal of Dental Research · doi:10.1177/0022034514560768 · Cited by 119

Authors: Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R.
Affiliations: Novartis (Switzerland) (CH)
University of Liège (BE)
ORCID: Bellahcène, Akeila
Venue: The Journal of Pharmacology and Experimental Therapeutics
Publisher: Elsevier BV
Published: 2002-01
Volume: 302
Issue: 3
Pages: 1055-1061
ISSN: 0022-3565 (ISSN-L)
DOI: 10.1124/jpet.102.035295
OpenAlex: W2144860907
Cited by: 854
References: 33
Citations by year: 2026: 13 · 2025: 17 · 2024: 14 · 2023: 20 · 2022: 17 · 2021: 18 · 2020: 22 · 2019: 34 · 2018: 23 · 2017: 20 · 2016: 24 · 2015: 38 · 2014: 46 · 2013: 44 · 2012: 36
FWCI: 14.78
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
PubMed (publishedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: zoledronic acid, bisphosphonates, antiangiogenic activity, angiogenesis inhibition, endothelial cell proliferation, basic fibroblast growth factor, vascular endothelial growth factor, endothelial cell adhesion, endothelial cell migration, tumor-induced osteolysis, malignant bone disease, chorioallantoic membrane assay
MeSH terms: Zoledronic Acid, Pamidronate, Cell Adhesion, Cell Cycle, Cell Movement, Cells, Cultured, Chemotaxis, Chorion, Diphosphonates, Endothelium, Vascular, Growth Substances, Humans, Imidazoles, Lymphokines, Muscle, Smooth, Vascular, Fibroblast Growth Factor 2, Endothelial Growth Factors, Apoptosis, Image Cytometry, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks